Uveitis is an intraocular inflammation that partly or totally affects the iris, ciliary body and choroid, whose causes are not always known and may be varied: ocular trauma or systemic diseases of genetic, immune or infectious origin. Uveitis can be acute or chronic, or duration. During chronic uveitis, the untreated and prolonged inflammation can spread and affect other ocular structures, as lens, vitreous, retina, optic nerve, leading to cataract, glaucoma, macular oedema, and leads to loss of vision.

In this study we suggest using a model of chronic uveitis in rabbits induced by Mycobacterium tuberculosis antigen to test efficacy of corticosteroid treatment. This predictive model will be amenable to evaluate compounds and medical devices in persistent uveitis that require long-term treatment.

Method

Twenty adult New Zealand albino rabbits were preimmunized by subcutaneous injection of Mycobacterium tuberculosis antigen H37Ra (10 mg – 0.5 ml Mineral oil on day 1 (1)). Uveitis was induced by intravitreal injection of antigen prepared from H37Ra (2.5 µg in 50 µl of saline solution) in all preimmunized animals on day 15. Induction was immediately followed by a single intravitreal injection of triamcinolone acetonide (TAA), 2 mg, or saline solution (Vehicle). A second H37Ra 2.5 µg intravitreal challenge was performed in both groups two weeks after the first challenge, without additional treatment.

Clinical signs of uveitis in anterior chamber and vitreous were scored by slit lamp observation twice a week after the challenges, then weekly for 2 months. At the end of the study (week 10), eye globes were collected and examined by histology (hematoxylin/eosin/safran staining).

Results

(A) Anterior chamber: adapted scale from G.J. Jaffe et al. (1) and S. Eperon et al. (2), iris congestion and aqueous cell density: 0: none, 1: mild, 2: moderate, 3: severe, additional scores were attributed for absence (0), or presence (1), of fibrin of synchiae and for normal (0), abnormal (1) iris dilation (maximum score = 9).

(B) Posterior chamber: vitreous opacity from 0 to 4 (Nussenblatt scale), absence (0) presence (1) of floating bodies in the vitreous, of deposits on lens, and normal (0), abnormal (1) fundus (retinal detachment, oedema, retinal tear… ) (maximum score = 7).

(C) Typical slit lamp pictures of anterior segment (left row) and fundus (right row) one week after the second challenge for: TAA treated rabbits (a) and (b), and Vehicle treated rabbits (c), (d), (e) and (f).

Clinical signs of uveitis were observed in two days after the first intravitreal challenge in vehicle treated rabbits. Slit lamp examination revealed inflammatory state in the anterior chamber with cells infiltration, iris, and haze in the vitreous (Fig-2-C-c, d, e and f, for illustration). The second challenge induced a stronger and more sustained inflammatory response. TAA treatment significantly reduced inflammation all along the study. Histological analysis indicated signs of panuveitis in the Vehicle treated animals: inflammation of the iris and ciliary body with exudate in aqueous humor (Fig-3-C-d, e), degenerative vitreous with fibrous material and inflammatory cells, cells infiltration in the retina and in the optic nerve head and some retinal detachment or disorganization of retinal layers (Fig-3-C-f). TAA treated animals showed less cells infiltration and a preserved retina (Fig-3-C-a, b, c).

Conclusion

Here was presented an experimental model of chronic uveitis in rabbit where a single administration of TAA reduced inflammation. This rabbit model of chronic anterior and posterior uveitis can be used to test efficacy of long-term treatment and delivery devices, due to the appropriate size of rabbit eye.